12th International Conference of Pharmaceutical Sciences

Venous thromboembolism (VTE) is a severe pathological condition of high worldwide incidence. Rivaroxaban is an oral anticoagulant available for VTE treatment and prevention. Despite the advantages associated with its administration over other anticoagulants, there are disadvantages to pharmacokinetic parameters and hemorrhagic conditions may appear. The transdermal delivery could overcome those disadvantages in association with a pharmaceutical nanosystem, as microemulsions. The work aims the development of microemulsions for transdermal administration of rivaroxaban. The formulations were prepared using propylene glycol, Labrasol®, isobutanol, Azona® and water. The droplet size obtained was 8-50 nm with polydispersity index of 0.1-0.3 by dynamic light scattering. The release assay was performed in a Franz Cell, the rivaroxaban released from formulation was about 50µg/mL, determined by High Performance Liquid Chromatography. The samples obtained were tested by Prothrombin Time and Active Partial Thromboplastin Time assays and were able to extend the clotting time in a biologically significant way.